Literature DB >> 27771864

Echinocandin Resistance in Candida Species: a Review of Recent Developments.

Nathan P Wiederhold1.   

Abstract

The echinocandins are important agents for the treatment of invasive fungal infections, especially those caused by Candida species. However, as with other antimicrobial agents, microbiologic resistance to this class of antifungal agents has emerged and can result in clinical failure. Several studies have recently reported an increase in echinocandin resistance in Candida glabrata isolates at various medical centers in different geographic regions of the USA. Recent studies have also reported that many of these isolates may also be fluconazole resistant, leaving few treatment options available for clinicians to use in patients with invasive candidiasis caused by this species. Our understanding of the clinical relevance of specific point mutations within the FKS genes that cause echinocandin resistance and risk factors for the development of microbiologic resistance and clinical failure have also increased. The purpose of this review is to discuss echinocandin resistance in Candida species and recent reports that have increased our understanding of this growing clinical problem.

Entities:  

Keywords:  Anidulafungin; Antifungal resistance; Candida; Candida glabrata; Caspofungin; Echinocandin resistance; FKS1; FKS2; Micafungin

Year:  2016        PMID: 27771864     DOI: 10.1007/s11908-016-0549-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  58 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrata.

Authors:  Yanan Zhao; Yoji Nagasaki; Milena Kordalewska; Ellen G Press; Ryan K Shields; M Hong Nguyen; Cornelius J Clancy; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.

Authors:  Maiken Cavling Arendrup; Juan-Luis Rodriguez-Tudela; Steven Park; Guillermo Garcia-Effron; Guillaume Delmas; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

6.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

7.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

8.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

9.  Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Authors:  Annette W Fothergill; Dora I McCarthy; Mohammad T Albataineh; Carmita Sanders; Maria McElmeel; Nathan P Wiederhold
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

10.  Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014.

Authors:  Snigdha Vallabhaneni; Angela A Cleveland; Monica M Farley; Lee H Harrison; William Schaffner; Zintar G Beldavs; Gordana Derado; Cau D Pham; Shawn R Lockhart; Rachel M Smith
Journal:  Open Forum Infect Dis       Date:  2015-12-14       Impact factor: 3.835

View more
  14 in total

Review 1.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

2.  The unmet clinical need of novel antifungal drugs.

Authors:  Damian J Krysan
Journal:  Virulence       Date:  2017-02-17       Impact factor: 5.882

Review 3.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 4.  Antifungal Resistance: a Concerning Trend for the Present and Future.

Authors:  Joshua A Hendrickson; Chenlin Hu; Samuel L Aitken; Nicholas Beyda
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

Review 5.  Clinical utility of antifungal susceptibility testing.

Authors:  Todd P McCarty; Paul M Luethy; John W Baddley; Peter G Pappas
Journal:  JAC Antimicrob Resist       Date:  2022-06-28

6.  Micafungin Enhances the Human Macrophage Response to Candida albicans through β-Glucan Exposure.

Authors:  José Pedro Guirao-Abad; Ruth Sánchez-Fresneda; Francisco Machado; Juan Carlos Argüelles; María Martínez-Esparza
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults.

Authors:  Roeland E Wasmann; Rob Ter Heine; Eric P van Dongen; David M Burger; Vincent J Lempers; Catherijne A Knibbe; Roger J Brüggemann
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 8.  Recent Insights into the Paradoxical Effect of Echinocandins.

Authors:  Johannes Wagener; Veronika Loiko
Journal:  J Fungi (Basel)       Date:  2017-12-28

9.  A case report of purulent pericarditis caused by Candida albicans: Delayed complication forty-years after esophageal surgery.

Authors:  Joowhan Sung; Irving Enrique Perez; Addi Feinstein; David Kidd Stein
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  The Magnitude of Candida albicans Stress-Induced Genome Instability Results from an Interaction Between Ploidy and Antifungal Drugs.

Authors:  Ognenka Avramovska; Meleah A Hickman
Journal:  G3 (Bethesda)       Date:  2019-12-03       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.